Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bergen Psychosis Project 2 - The Bergen-Stavanger-Innsbruck-Trondheim Study

Next Previous
Search
Trial Profile

Bergen Psychosis Project 2 - The Bergen-Stavanger-Innsbruck-Trondheim Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amisulpride (Primary) ; Aripiprazole (Primary) ; Olanzapine (Primary)
  • Indications Psychotic disorders; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms Best Intro Study; BP2

    • Most Recent Events

    • 01 Mar 2022 Results comparing the influence on CRP levels of three pharmacologically diverse new generation antipsychotics during a one-year follow-up in schizophrenia spectrum disorder., published in the Schizophrenia Research
    • 30 Apr 2021 Results (n=144) assessing comparison of the antihallucinatory effectiveness of 3 pharmacologically different antipsychotics: olanzapine, amisulpride, and aripiprazole. published in the Journal of Clinical Psychopharmacology
    • 04 Oct 2011 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top